ATLANTA–(EMWNews)–MIV Therapeutics, Inc. (OTCBB:MIVI) (Frankfurt:MIV), a leading

developer of next-generation coatings and advanced drug-delivery systems

for cardiovascular stents and other implantable medical devices,

announced that senior research analyst Kenneth Siri, CFA, of Jesup &

Lamont Securities, maintained his Buy rating for MIV Therapeutics and

adjusted his target price to $20.00 to reflect the Company’s

recent 1-for-10 reverse stock split.

In a research note on July 8^th, Jesup & Lamont

stated that the split is designed to improve the stock’s

marketability to institutional investors. As a result of the 1-for-10

reverse split, Siri is adjusting his price target from $2.00 per share

to $20.00 per share.

Jesup also notes that MIV has the potential to penetrate the

drug-eluting stent (DES) market by addressing DES safety concerns, while

maintaining efficacy and targeting additional lesions currently out of

reach of DES. Additionally, Siri believes that the company’s

drug delivery technology (hydroxyapatite or HAp), requires little

modification for orthopedic use, making MIV a prospective player in

orthopedic drug delivery.

Below is a link to the research note:

http://www.mivtherapeutics.com/_resources/articles/070808-Jesup-

Lamont.pdf (Due to its length, this URL may need to be

copied/pasted into your Internet browser’s address field. Remove

the extra space if one exists.)

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced

biocompatible coatings for passive and drug-eluting applications on

cardiovascular stents, as well as for a broad range of other implantable

medical devices. The Company’s ultra-thin coating formulation is

designed to protect surrounding tissue from potentially harmful

interactions with bare metallic stents. This coating platform is derived

from hydroxyapatite (HAp), an organic material that has demonstrated

excellent in vivo safety and biocompatibility. Hydroxyapatite is

a porous material that makes up the bone mineral and matrix of teeth,

and is widely used today as a bone substitute material and for coatings

on implantable fixation devices in orthopedic, dental and other

applications. The Company’s novel polymer-free drug-eluting technologies

based on HAp could also provide an attractive alternative to current

polymer-based drug-eluting coatings on the stent market, which have been

associated with undesirable effects. The Company’s drug-eluting coatings

are additionally designed to suit a broad range of implantable medical

devices that could benefit from highly customizable drug release

profiles. MIV Therapeutics has a Collaborative Research Agreement with

the University of British Columbia and has received a government grant

for its research program on the “Development

of Novel Drug Eluting Composite Coatings for Cardiovascular Stents,”

under the National Research Council-Industrial Research Assistance

Program. Under this sponsorship, the Company is expected to complete its

drug-eluting research and development program and to reach product

commercialization. MIV’s intellectual property portfolio includes

patents held by the University of British Columbia and exclusively

licensed to MIV. Key patent applications filed simultaneously in various

countries around the world further protect the commercial exclusivity of

MIV’s inventions in the global marketplace. For more information, please

visit www.mivtherapeutics.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters

discussed in this press release are forward-looking statements. All

statements that discuss expectations and projections with respect to

future matters including, without limitation, statements relating to the

safety and efficacy of the Company’s product

and the ability of the Company’s product to

rejuvenate the stent market are forward-looking statements. Such

statements are indicated by words or phrases such as “proposed,”

“expected,” “believe,”

“will,” “breakthrough,”

“significant,” “indicated,”

“feel,” “revolutionary,”

“should,” “ideal,”

“extremely” and “excited.”

Such statements include but are not limited to that the split is a

positive move and will result in an increase in attractiveness to

institutional investors. These statements are made under “Safe

Harbor” provisions of the Private Securities

Litigation Reform Act of 1995. Actual results may differ materially from

those described in forward-looking statements and are subject to risks

and uncertainties including, without limitation, market acceptance of

the Company’s product, the ability of the

Company to raise sufficient funding and to continue to develop its

various business interests as presently contemplated, and other factors

identified in the Company’s filings with the Securities and Exchange

Commission including, without limitation, the Company’s annual report on

Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The Company

expressly disclaims any obligation to update publicly or otherwise

revise these statements, whether as a result of new information, future

events or otherwise, except to the extent required by law.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions